EPARs human use - Neupro//Rotigotine

FICHA FARMACOLÓGICA de Rotigotine. Contiene la Monografía en distintos idiomas (de la Comunidad Económica Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Cerasale. MAYO 30, 2009.-

abrir aquí:
EPARs for authorised medicinal products for human use - Neupro

Active Substance
Rotigotine
International Nonproprietary Name or Common Name
Rotigotine
Pharmaco-therapeutic Group
Dopamine agonists
ATC Code
N04BC09

Therapeutic Indication:
Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations)

Restless Legs Syndrome: Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in adults.

Date of issue of Marketing Authorisation valid throughout the European Union
15 February 2006